Novartis Series C Preferred Stock Financing for Akebia

In June 2013, our lawyers represented Novartis Bioventures in a $41,000,000 Series C Preferred Stock financing for Akebia Therapeutics, Inc. Akebia Therapeutics, Inc., based in Cincinnati, Ohio, is a biopharmaceutical company that engages in the discovery and development of small molecules for the treatment of anemia and vascular disorders. Akebia Therapeutics, Inc. was founded in 2007. Novartis Bioventures, is a venture fund based in Cambridge, Massachusetts.
Posted on June 4, 2013